# HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)

> **NCT06634420** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Intellia Therapeutics** · enrollment: 80 (actual)

## Conditions studied

- Hereditary Angioedema

## Interventions

- **BIOLOGICAL:** NTLA-2002
- **BIOLOGICAL:** Normal Saline IV Administration

## Key facts

- **NCT ID:** NCT06634420
- **Lead sponsor:** Intellia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-15
- **Primary completion:** 2026-02-10
- **Final completion:** 2027-09
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06634420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06634420, "HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06634420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*